Montelukast: The New Therapeutic Option for the Treatment of Epilepsy
Open Access
- 1 January 2021
- journal article
- review article
- Published by Taylor & Francis Ltd in Journal of Experimental Pharmacology
- Vol. ume 13, 23-31
- https://doi.org/10.2147/jep.s277720
Abstract
Currently, there is no definitive cure for epilepsy. The available medications relieve symptoms and reduce seizure attacks. The major challenge with the available antiepileptic medication is safety and affordability. The repurposing of montelukast for epilepsy can be an alternative medication with a better safety profile. Montelukast is a leukotriene receptor antagonist that binds to the cysteinyl leukotrienes (CysLT) receptors used in the treatment of bronchial asthma and seasonal allergies. Emerging evidence suggests that montelukast’s anti-inflammatory effect can help to maintain BBB integrity. The drug has also neuroprotective and anti-oxidative activities to reduce seizure incidence and epilepsy. The present review summarizes the neuropharmacological actions of montelukast in epilepsy with an emphasis on the recent findings associated with CysLT and cell-specific effects.Keywords
This publication has 65 references indexed in Scilit:
- Open study of pranlukast add-on therapy in intractable partial epilepsyBrain & Development, 2013
- The role of inflammation in epilepsyNature Reviews Neurology, 2010
- Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug DevelopmentPharmaceuticals, 2010
- Eicosanoids and cancerNature Reviews Cancer, 2010
- Montelukast Inhibits Matrix Metalloproteinases Expression in Atherosclerotic RabbitsCardiovascular Drugs and Therapy, 2009
- Injury-Related Production of Cysteinyl Leukotrienes Contributes to Brain Damage following Experimental Traumatic Brain InjuryJournal of Neurotrauma, 2009
- Phospholipases A2 and Inflammatory Responses in the Central Nervous SystemNeuroMolecular Medicine, 2009
- Pharmacological modulation of the leukotriene pathway in allergic airway diseaseDrug Discovery Today, 2007
- Leukotriene D4 induces brain edema and enhances CysLT2 receptor-mediated aquaporin 4 expressionBiochemical and Biophysical Research Communications, 2006
- The role of inflammation in CNS injury and diseaseBritish Journal of Pharmacology, 2006